

Lightning Talks

EVIDENT Proposers' Day
12.10.25

Company Name



- Osmind is a psychiatry-specific technology and real-world evidence company
- We've had a strategic focus on interventional psychiatry and psychedelics since our founding in 2020
- Startup based in San Francisco, backed by leading healthcare technology investors
- Contact: Jimmy Qian, Co-founder and President
 - Email: jimmy@osmind.org
 - Work cell: (415) 226-9817
 - www.osmind.org

Core Capabilities

First, we offer a clinic operating system **for** psychiatry clinics



Our platform provides **differentiated access**



We use this access **for** life sciences & research

All-in-one: EHR + practice management software, patient app, full-stack billing services, practice support & development services, clinician community

1. Engaged network of clinics
2. Direct, active network of patients
3. Full real-world data (clinical + billing)
4. Full control over technology platform

Real-world evidence, patient registries, retrospective and prospective studies, decentralized trials, randomized controlled trials, mixed-methods studies

Strengths / Capability Highlights

- Largest network of interventional psychiatry practices in the US, with 800+ independent practices across 49 states
- Our data and access spans interventional psychiatry (ketamine, esketamine, TMS, etc.) as well as regulated psilocybin services across Oregon and Colorado
- Successfully executed 15+ projects in interventional psychiatry / psychedelics with 10+ biopharma partners
- Strong research track record in ketamine and psychedelics:
 - Conducted the first-ever real-world evidence study from regulated psilocybin services in the US
 - Published the largest real-world analyses of ketamine for depression
 - Published the largest real-world analysis of ketamine for PTSD

Teaming Goals

- Osmind has executed successful projects across:
 - Digital phenotyping for biomarker development
 - Multimodal data capture during real-world rapid-acting treatment sessions
 - Precision patient recruitment into trials
 - Response prediction in rapid-acting therapeutics
- For EVIDENT, we're building off ongoing projects with our existing partners. Legal agreements, technology and data integrations, scientific setup, and recruitment flows are in place from ongoing collaborations.
- While Osmind already has a set of exclusive teaming partners, we are open to incorporating additional teaming opportunities, e.g. hardware or phenotyping technologies that could supplement our study approach.



Sunstone Therapies

sunstonetherapies.com

Dr. Manish Agrawal, CEO

manish.agrawal@sunstonetherapies.com

301-580-1711 | Rockville, MD

sunstone
THERAPIES

- First purpose-built center for psychedelic delivery and research in the U.S. (est. 2020)
- Treated more patients with non-ketamine psychedelics in the past 24 months than any other org. in the world
- Agile independent organization - not govt. or academic affiliated/funded
- Fast/Flexible teaming agreements
- Fast/Flexible IRB process (2-3 weeks to approval)
- Priority populations: PTSD, depression, advanced illness, Veterans, sexual trauma, cancer



Core Capabilities

- Industry leaders in Psychedelic-Assisted Therapy research and delivery: to date 420 treatments, 16 trials, 14 publications, 8 compounds
- Streamlined industry sponsored trials and IITs focusing on delivery of care
- Proven operational and training models may inform Psychedelic-Assisted Therapy at scale
- Upcoming: 2 trials Q1 '26 122 participants, 1 trial Q2 '26 200 participants
- Access to past participants for ongoing longitudinal mixed methods research



Strengths /Capability Highlights

- Speed in designing, conducting and completing trials
- High patient volume, multiple indications and compounds, both individual & group care models
- Training expertise and capability across multiple indications and compounds, tiered supervision, and actual patient experience
- Ability to collect audio video data, large data set on four completed trials, two set to launch Q1 '26, multicenter 200 veteran trial launch Q3 '26
- CRM, EHR, EDC, Vault audio video
- Ability to study set and setting, facilitator/patient relationship, clinical outcomes, cost outcomes
- Ability to study alternative delivery models (dyad, group vs individual) and alternative cost models (value based care)



Teaming Goals

- Existing Collaborations: University of Vermont, ASU, Kernel, Mount Sinai, Compass, Resilient, Reunion, Cybin, Transcend, Usona, Adventist Healthcare, Deliberate AI, State of Illinois, State of MD
- No conflicts of interest - independent organization
- Strong desire to team with: translational partners; we bring the clinic delivery and outcomes and can partner with drug developers, payers, biological labs, technology companies, designing for value based care and affordability grounded in outcomes
- Strong desire to support follow-on dev't effort as premier research partner to ARPA-H
- Vision: scientific rigor to shape care delivery of Psychedelic-Assisted Therapy at scale

Deliberate AI

New York technology startup (Small Business)



Carnegie Mellon University  University of Pittsburgh

Founding team combined h-index: 123

Contact: Marc Aafjes CEO
marc@deliberate.ai | 213-510-7773

Core Capabilities:


Multimodal Biomarker Fusing & Individualized Phenotypes



- 1. Full stack digital phenotyping:**
 - audio + video (in-person and remote)
 - mobile passive sensing
 - biometric passive sensing



- 2. Proprietary multimodal fusion ML**
 - (multiplex) biomarker fusing
 - psychotherapy analysis



- 3. Translation / regulatory**

Strengths / Capability Highlights

- **Pioneering FDA I STAND milestone**
 - First AI & Digital Health
 - First Neuroscience/Psychiatry
 - FDA U01 grant: world's first GenAI non-inferiority RCT
- **Pre-trained multitask models:**
 - Depression, Anxiety, PTSD, Suicide
 - Therapeutic alliance
- **Multimodal ML performance**
 - \$20m NIMH U01: Mount Sinai, IBM, etc.
 - DARPA NEAT, NIMH SBIR, Wellcome, Boehringer Ingelheim Innovation Award



Teaming Goals

- **Seeking clinical partners to plug into our FDA-ready validation engine**
- **What we offer:**
 - Funded comparator cohort (n=630)
 - TA1+3: Turnkey A/V measures, digital phenotyping & multimodal fusion
 - TA2: audio-video, dyadic analysis

Company Name

kernel

- Startup founded in 2016
- Venture-backed with \$140M+ raised
- Based in Los Angeles, CA
- Contact information
 - <https://www.kernel.com>
 - Ryan Field, PhD
 - CEO & CTO
 - ryan.field@kernel.com
 - +1 323-248-1801

Core Capabilities

- Developer of multi-modal brain measurement platform combining **Time-Domain Near-Infrared Spectroscopy (TD-NIRS) with EEG**
- Full-stack hardware, software, neuroscience, data science company
- Expertise in developing functional brain-based biomarkers

Strengths / Capability Highlights

- Kernel Flow brain measurement system (TD-NIRS + EEG) is unmatched on the market.
- Have run successful real-world observational studies to develop biomarkers for **depression** and **mild cognitive impairment**.
- Preliminary TMS response prediction biomarker is **~90% accurate**.
- Currently supporting 2 sponsored interventional trials



Teaming Goals

- Kernel is a strong interdisciplinary team focused specifically on measuring the brain at scale.
- Typically team with external clinicians and groups developing interventions.
- Would like to team with groups seeking to **build large, standardized datasets with high-quality clinical labels**.
- Specific interest in teaming to pair clinic-based Kernel measurements to continuous measurements with wearables/digital technologies.

Company Name



- Growth Stage Medtech AI in Neurology
- Nationally Deployed
- SoC2 Type II, GDPR, HIPAA
- epitel.com
- Mark Lehmkuhle, PhD, CTO, Founder
 - Lehmkuhle@epitel.com
 - 734-646-6266

Core Capabilities



- 5 FDA Clearances
 - 30-day wireless wearable EEG
 - Machine Learning Detection of Seizures
 - Cloud-based remote patient monitoring
 - Peds age 1 through adults
- Reimbursable Through Existing EEG CPT Codes

Strengths / Capability Highlights



Accurate - provides high-fidelity EEG recordings

Wireless - allows patients to move freely w/o wires

Fast - enables EEG monitoring within minutes

Familiar - comfortable day and night

Efficient - weeks of EEG data analyzed in minutes with REMI Vigilenz AI


Teaming Goals

We are looking to partner with teams who have a **rapid therapeutic for behavioral health** who could employ **quantitative EEG metrics**

- Record before intervention
 - ID responders
- Record during intervention
 - Determine in-session changes
- Record after intervention
 - Efficacy of therapeutic



Drug > Neutral




**fMRI Drug Cue Reactivity (FDCR)
along with Multimodal Craving Data as an
FDA Qualified Objective Measure for
Rapid Response in Addiction Treatment**

Hamed Ekhtiari, MD, PhD
(Division Chief of Addiction Psychiatry)
(hamed.Ekhtiari@utsouthwestern.edu)




Me! Manish Jha Abigail Ortiz Andre Brunoni Tarek Rajji

Strengths / Capability Highlights



Teaming Goals



Company Name

Zachary Cohen and the Personalized Treatment Lab at the
University of Arizona
[https://sites.arizona.edu/personalized-treatment-lab/team/
cohenzd@arizona.edu](https://sites.arizona.edu/personalized-treatment-lab/team/cohenzd@arizona.edu)

+

Jessica Schleider and the Lab for Scalable Mental Health at
Northwestern University
<https://www.schleiderlab.org/labdirector.html>
jessica.schleider@northwestern.edu

+

Shravan Aras: SensorFabric and SensorLab at the
University of Arizona
shravanaras@arizona.edu

POC - Zach's cell: (508) 654-8255

Core Capabilities

Key areas of work:

- Digital Therapeutics
- Precision Mental Health
- Machine Learning / Predictive Modeling
- Personalized Treatment Approaches
- Treatment Development
- Digital Phenotyping / Passive Sensing
- Dissemination and Implementation
- Single-Session Interventions (SSI)
- Modular/Transdiagnostic Interventions
- Measurement
- Intensive Longitudinal Data
- Big Data Approaches (including individual-participant-data meta-analysis [IPDMA])

Strengths / Capability Highlights

Highlight your specific contributions

- Project Yes / Koko : <http://www.tryprojectyes.org>
- RainFrog Digital Therapy Ecosystem
 - U of A Digital Mental Health Tools (DMHTools)
 - STAND Digital Therapy
- IPDMA - <https://doi.org/10.1371/journal.pone.0322124>
- SensorLab: <https://sensorlab.arizona.edu>
- SensorFabric: <https://cb2.arizona.edu/services/sensor-analysis>

Teaming Goals

We are looking for potential implementation partners to collaborate in D&I, evaluation of implementation success across different agencies, counties, states, etc. in later-phase deployment



David Crowley, dcr@empatica.com, (617) 599 6107

Health Monitoring Platform

AI-based cloud analytics platform and medical devices to support Clinical trials Management and Remote Patient Monitoring.


Digital Biomarkers

Development and launch of novel Biomarkers targeted as Diagnostic/Therapeutic component for existing and new drugs

- 3 global locations
- 100k+ devices
- 300+ measures



Core Capabilities



Health Monitoring Platform



Medical Device Design and Production



Clinical Trial Operations



Digital Biomarker Development

Strengths / Capability Highlights



FDA Cleared



Teaming Goals



Garmin Health

- Traditional- Large
- Olathe, Kansas
- www.garmin.com/en-US/health/
- Spencer Posey-
Military & Human Performance Lead
Spencer.posey@garmin.com
443-536-9893

Core Capabilities

- Device and sensor technology - PPG, ECG, SPO2, HRV
- Embedded Engineering and Firmware - real time sensors
- Software platform, API's and SDKS - data integration
- Health Algorithms and Validation - Sleep, HRV, Respiration
- Clinical and Healthcare Solutions - Bridges gap by wearables
- Partnerships and Commercialization -Broad partnerships
- Security and Compliance - Frameworks, encryption

Strengths / Capability Highlights

- Garmin offers the following capabilities
- High Quality Sensor Data allowing for research
- Long Battery Life measured in Weeks / Months vs hours
- Wide range of wearables ranging in price, form, function
- Garmin Health ecosystem - API, SDK, Real Time Streaming, etc
- Vertical Integration - Garmin facilities, design, manufacture

Teaming Goals

- Interested in working with partners that want to utilize the rich data from Garmin wearables.
- Current teaming efforts to support military/DOW projects
- Other wearable companies can be a conflict, but also sometimes a complement
- Willing to support the follow-on development work, very low interest in adding to our tech stack without major benefit
- Prefer to work with all that could utilize Garmin wearables and services



- **Mission:** Optimize human health through the gut microbiome
- **Sector:** Biotechnology
- **Location:** Boston; 4,000+ sq. ft microbiology laboratory
- **Website + phone:** www.holobiome.org; 617-571-7522
- **People here today**
 - Philip Strandwitz, CEO and Founder; phil@holobiome.org
 - Gabriel Al-Ghaltith, VP Comp Bio; gabe@holobiome.org
 - Maddie Morrissette, Sr. Scientist; madeleine@holobiome.org

Core Capabilities

- **Full stack microbiome discovery platform**
 - Microbiome collection kit/donor network
 - Microbiome data on 120,000 people (public, private)
 - Advanced modeling (e.g. obese classifier - AUC 0.93)
 - Largest reported gut bacterial genome database (1.7M+)
 - Most diverse library of human gut bacteria (30,000+ isolates)
 - Throughput human gut simulator (enables n=1 experiments)
 - In-house deep long-read sequencing (+ novel comp. stack)
 - Screening expertise (e.g. target-directed; food <> microbe)
 - Deep domain knowledge on IP and regulatory

Strengths / Capability Highlights

- Mapping the interface of food, gut microbes, and ourselves
- We do this by combining large amounts of data from both a human- and microbe-first approach, identifying “superheroes”
- Insights inform products (probiotics, postbiotics, and prebiotics), which we develop as consumer products or drugs
- World experts in microbiology, microbiome research, gut-brain-axis, computational biology, and AI/ML (including agents)
- Lead programs in depression and pain. Discovery programs for metabolic health, stress, and longevity
- Active partnerships with Fortune 500 consumer and pharma

Teaming Goals

- Complex science cannot be translated without collaboration
- This means we owe it to patients to work together efficiently
- We want to offer the best of the microbiome to any project
- **Example collaborations:** Radicle Sciences (citizen science), Alden Scientific (digital twins), OneMind (mental health)
- **Success stories:** finding naturally occurring bacteria for depression and pain; n=1 auto-brewery syndrome case
- **Goal for the team:** find a scalable framework of discovery, intervention, and validation for mental health and beyond

Company Name

huru



Josh Eggleston
CEO, Co-Founder



Josh@hurulabs.com




Core Capabilities



A scalable platform for continuous EEG
and movement data collection

Strengths / Capability Highlights

- Deploy at 10,000+ participant scale
- Works globally—US and international
- HIPAA-compliant, secure
- Unobtrusive wearable
- Flexible configuration, single/multiple electrodes:



Teaming Goals

Huru = infrastructure. You = science.
Together = EVIDENT winners.

- Clinical leadership
- Existing/planned trials with IRB approval
- AI/ML teams for biomarker work
- Data integration expertise

TA's 1,2 & 3



Ksana Health



- AI-enabled behavioral health measurement + digital phenotyping platform
- Focus: Objective, scalable endpoints for mental/behavioral health improvement
- Footprint: U.S.-based with numerous academic + clinical partnerships
- Soc 2 Type 2 Certified, HIPAA compliant
- www.ksanahealth.com
- Contact
 - Dr. Nick Allen, CEO,
 - nick@ksanahealth.com

Core Capabilities

- Multimodal digital phenotyping using smartphones + wearables to quantify function, behavior, sleep, activity, language and change over time.
- Objective outcome modeling for rapid and durable response detection.
- Clinical workflow integration (measurement-based care support, clinician-facing dashboards).
- Longitudinal risk monitoring with within-person personalization.
- Data pipelines for research-grade and pragmatic trials (privacy-forward, scalable deployment).

Strengths / Capability Highlights

- **Digital endpoint innovation at scale:**
 - Ability to operationalize continuous, minimally invasive behavioral markers suitable for large, real-world cohorts—matching EVIDENT TA1 priorities for wearable + digital phenotyping signals.
- **Prediction + durability profiling:**
 - Methods for early response detection and 3-12 month durability forecasting, relevant to TA3.
- **Clinical + real-world evidence bridge:**
 - Strong fit for embedding objective measures alongside FDA-approved endpoints within interventional settings.

Teaming Goals

We are looking to partner with:

- TA1 collaborators: neuroimaging groups, wearable biosensor teams, and pharma/biotech with rapid-acting compounds to co-develop composite digital + biological endpoints.
- TA3 collaborators: clinical trialists and data holders to validate risk + response models across diverse populations.
- TA4 trial networks: sites running eligible rapid-acting interventional studies who want a plug-in digital phenotyping layer to contribute de-identified supplemental data to the ARPA-H repository.

We Bring: scalable deployment, digital endpoint R&D, analytics, and clinical integration.

Luna Labs has established capabilities to detect various biomarkers relevant to EVIDENT TA-1 and TA-3

Company

Luna Labs USA, LLC (<https://lunalabs.us>) is a Small Business and Non-Traditional Defense Contractor with 50,000 sq. ft. of research, development, and production space in Charlottesville and Blacksburg, VA. We are NIST Basic and NIST High (DIBCAC) compliant; NAICS Codes 541714 and 541715.


Core Capabilities

- Rapid Prototyping
- Diagnostic Design
- Device Engineering
- Biomarker Identification
- Antibody Screening
- Lateral Flow Assays
- Liquid Chromatography
- Mass Spectrometry

Strengths / Capability Highlights


REACT enables **rapid detection** of a single biomarker associated with neuronal damage (GFAP) at the point of injury

- **Rapid detection** provides a positive/negative result within minutes with no sample processing required.
- **Sample compatibility** enables the evaluation of a variety of biospecimens, including whole blood, plasma, or tears.
- **Specific and sensitive** lateral flow design with a limit of detection below 0.5 ng/mL.
- **Low cost** enables evaluation of patient response to therapeutic treatments over time.



AutoMASS supports the **comprehensive evaluation** of a blood specimen to detect multiple biomarkers with high sensitivity

- **Microfluidic sample preparation** enables rapid separation of serum from whole blood for analysis.
- **Capillary liquid chromatography** facilitates the separation of multiple biomarkers to enable detection with high sensitivity and specificity.
- **Portable mass spectrometry** enables highly specific multiplexed quantification of biomarkers and speeds time-to-result.
- **Automation** requires minimal user interaction.



Teaming Goals

Luna Labs is actively seeking collaboration with prime performers under Technical Area 1 or 3. We offer an experienced, agile team with established platform technologies that have been optimized to support the detection of relevant biomarkers to assess traumatic injury, mental health, or therapeutic efficacy. Our systems are readily customizable to individual use scenarios and can be adapted to detect alternative biomarkers to meet specific project needs.



Lauren Costella
434.220.9441
lauren.costella@lunalabs.us



YALE STRESS CENTER

Yale Stress Center

- Rajita Sinha, PhD - Founder and Director
- Academic, NE medical center setting
- Non-traditional, not tied to specific disease
- Certified health care and clinical research
- Facilities: conduct of clinical trials, digital therapeutics, remote and in-person data collection, health symptom and outcome assessment for stress-related illnesses.
- Provide health promotion skills training
- www.yalestresscenter.org
- Rajita.sinha@yale.edu; Tel: 203-737-5805

Strengths / Capability Highlights

Specific contributions:

- Disrupt disease-based medicine and build and validate prevention-based health
- Multi-domain assessments and interventions
- Restoring adaptive stress responses for health with individual health signatures
- Behavioral choice role in mental health
- AI technology development for multi-stream data on varying timescales (Open AI)
- Digital behavioral intervention dev. & testing
- Interdisciplinary approaches and personnel

Core Capabilities



Key areas of work:

- Disease and non-disease, prevention based
- Target areas: Stress-related physical health and mental health symptoms and outcomes
- Probing mechanisms, biomarkers and key health outcomes with treatments
- Web-based data collection, FDA and non-FDA trials; longitudinal outcomes
- Single- and central IRB and health system approval and IRB management
- Engineering, Technology and Data Science collaborations - ML/AI & digital capabilities

Teaming Goals

What are we looking for:

- Individual-level modeling of mental health outcomes to identify multi-level biomarkers of success/failure
- Ongoing and past teaming with pharma- and behavioral digital companies for RCTs
- No organizational Conflicts of Interest
- High interest in partnering on individual-level biomarker and signature of disease risk and treatment outcome research.
- High interest and ability to exclusively partner under CDA/CTAs.



mpathic: Human-centered AI Safety

- mpathic promotes safety in medical and regulated settings by improving AI systems using conversation analytics (SaaS/API), synthetic data, and expert human data services for validation. Series-A Start-up.
- www.mpathic.ai
- Located in Bellevue, WA
- HIPAA, SOC2-Type2, GDPR, FERPA, Part 11

Contact: Alison Cerezo, PhD
CSO & Licensed Psychologist
alison@mpathic.ai; 541/579-4455

Strengths / Capability Highlights

Proprietary behavioral NLP stack (e.g., patient characteristics and dyadic elements) with clinician-rated ground truth

Paralinguistic audio analytics for depression, suicide risk, and therapeutic relationship

Validated in real-world settings, including global and US-based FDA-regulated psychedelic trials

Secure, scalable platform with HIPAA, SOC2, and Part 11 compliance

Multidisciplinary team: Clinical psychologists, ML engineers, data scientists, regulatory consultants

Real-time AI Safety Monitoring for Clinical Trials & Healthcare

Multimodal capabilities: NLP + Audio + HRV for real-time modeling of therapeutic and clinical interactions.

Psychedelic & CNS Clinical Trials: AI detection of clinical risk, safety events, patient characteristics, and therapeutic fidelity.

Dyadic Interactions: Automated monitoring of interpersonal and therapy dynamics (e.g. trust, synchrony, and alliance mapping) from recorded sessions

Mental Health Domains: Behavioral markers of depression, PTSD, suicide risk; early detection and responsiveness.

Project Goals

TA2: Dyadic session data for predictive modeling of meaningful clinical change in depression and PTSD.

- We work with several of the leading psychedelic drug developers to conduct AI monitoring on their recorded psychological support sessions. We have 100+ AI models specifically designed to evaluate in session data from participants and facilitators
- We specialize in detecting subtle behavioral inflection points—such as increased agency, emotional expressiveness, and alliance formation—that align with ARPA-H goals for rapid in-session improvement.
- We are open to: Serving as **lead** on a funded effort Providing the **tech solution** for research teams seeking to enhance their clinical trial data with multimodal behavioral analytics

Company Name




TELEDYNE SCIENTIFIC COMPANY Intelligent Systems Laboratory

- Specialized Lab in a Large Company
- Located in Research Triangle Park, NC
- Collaborations with Duke, UNC, and NC State
- SCIFs, Prototyping Shop, Private Cloud, Electronics Laboratory, Sleep Lab
- <https://www.teledyne.com>
- Michael P. Weisend, Fellow and Senior Principal Neuroscientist
 - michael.weisend@teledyne.com
 - 505-480-9789

Core Capabilities

Neuroscience, AI/ML, Autonomy

- Neuroimaging (EEG, MEG, MRI, Ultrasound)
- Neuromodulation (TES, TMS, VNS, tFUS)
- Mental Health (Suicidality, Schizophrenia, PTSD, Sleep)
- Hardware and software system integration for closed-loop interventions
- Wearable development and prototyping



Strengths / Capability Highlights

- Wearable neuroimaging and neuromodulation (EEG and TES) with Custom, AI-Supported Brain Computer Interface (BCI) Hardware and Software
- Phantoms for algorithm testing in EEG, MEG, and NIRS
- On site and at home human subjects testing in over 18 years of continuous DARPA funding for neuroscience, wearables, signal analysis and algorithm development
- Multidisciplinary Staff (physics to psychology)

Teaming Goals

- We are looking for a **clinical trial partner**.
- We have an idea in support of TA2 that leverages the neuroscience of insight.
- Possible teaming with UCSD Radiology for high resolution neuroimaging and Zeto for in-session EEG recordings.
- A follow on effort for development of device for commercialization is certainly interesting.
- No conflicts of interest (except the usual).
- Happy to team exclusively when the team can meet or exceed the goals of the program.

Oui Therapeutics,

- Small business headquartered in New Haven, CT
- Established compliance for FDA-regulated activities, HIPAA protections, and IRB oversight
- Developer of digital therapeutics for suicide risk, mental health, and trauma-related conditions
- <https://ouitherapeutics.com>
- Brian Keenaghan | 203.725.4024 | brian@ouitherapeutics.com

Core Capabilities

- Evidence-based digital therapeutics for high-risk behavioral-health populations
- Digital platform optimized for integration with wearable physiologic data (HRV, sleep, activity)
- Multimodal clinical + digital + physiologic datasets
- Deep experience researching FDA-regulated digital therapeutics
- Expertise scaling digital health products in real-world settings

Strengths / Relevant Experience

10 completed or active federally-funded digital therapeutic trials:

Active trial (1) OTX-207 (Teen suicide reduction): NIMH-funded multisite RCT

- Built on OTX-202 (Adult suicide reduction) with 58% reduction in attempts among prior attempters (JAMA Open Network)

Active trial (2) OTX-601 (Adult suicide reduction): NIMH-funded multi-phase RCT with dosing complete and pilots launching

Active trial (3) OTX-202 (Active duty military suicide reduction): DOD-funded RCT

Teaming Goals

- Partners for wearable biosignal integration, passive sensing, and data fusion
- Co-development of objective, real-world behavioral-health endpoints
- Expansion to Veteran, DoD, and high-risk civilian populations
- Collaborators for biological supplement data (TA4), risk modeling, and scalable implementation



- #1 U.S. generator of rigorous clinical evidence on wellness interventions
- Founded in 2020 in San Diego, ~40 FTEs
- www.radiclescience.com
- Grace Lightfoot, grace@radiclescience.com
Senior Director of Clinical Engagement

Core Capabilities

- Next gen AI-enabled decentralized & hybrid trials
- 10x speed and cost improvements
- Fully integrated in-house operations end-to-end
- Rigorous health & behavior data, real world settings
- Clinically validated D2C measures: PROs; lab biomarkers, digital (AI facial scanning, neurocognitive assessments), connected devices (wearables, bluetooth scales, CGM)

Strengths / Capability Highlights

- Completed blinded randomized placebo controlled trials on 80,000+ Americans since 2021 launch
- Enrolled unprecedented representation with 50% women, 25% minorities and 20% rural populations
- Studying foods, beverages, supplements, digital therapies, and diagnostics across 20+ health areas

Teaming Goals

- Accelerated R&D, data for patents, claims substantiation, precision subpopulation insights, and real-world evidence
- **ARPA-H grant proposal:** Mental health 21-arm trial on 6000 Americans with Holobiome on prebiotic fiber blends
- **Sponsor examples:** 1020 American, 5-arm double-blinded RCT on natural compounds published in *Pharmaceuticals*
- Some of history's largest supplement trials for sleep, anxiety, and pain ~ sponsored by Cedar Sinai physicians



Company Name

Sabba Collective, Inc

sabba

- AI-native training & education platform for frontier mental health, with a focus on psychedelic therapies
- Startup (Public Benefit Corporation) based in NYC
- Website: www.sabba.com
- Platform for U-PEP (www.upep.org): University Psychedelic Education Program: 33+ universities developing evidence-based psychedelic education
- Jeremy Rudy (CEO), former Coursera
 - jeremy@sabba.com | 929-373-2729

Core Capabilities

- AI-native learning infrastructure for skill development across therapist + care team roles
- Multimodal ingestion + analysis of educational and clinical content (text, audio, video)
- Dyadic communication modeling and feedback tools to support high-fidelity therapeutic training
- Training series with master clinicians & case videos to ground models in real-world facilitation expertise developing evidence-based psychedelic education
- Ability to standardize and structure large, heterogeneous content sets for research and workforce development

Strengths / Capability Highlights

- National-scale network reach: 33+ universities & 20+ orgs generating diverse content, providing large-scale insights and rapid dissemination of new evidence-based training materials
- Proven ability to structure complex qualitative content – case videos, expert instruction, session materials – into usable, research-ready formats
- Best-in-class UX for clinicians, faculty, and students, enabling strong engagement and adoption across academic, training, and clinical environments

Teaming Goals

- Seeking partners in TA2 (dyadic interaction measurement) **and** TA4 (lightweight data capture & standardization)
- Open to teaming with academic centers, clinical trial sites & primes building neuroplasticity-assisted therapy infrastructure
- Interested in supporting efforts requiring training, skill development, content structuring, and therapist performance evaluation
- Flexible teaming models; eager to collaborate to advance safety, fidelity, and accessibility in emerging mental-health modalities

SRI International

- Non-Profit Independent Research Institute
- HQ: Menlo Park, CA, Many other sites
- Certified systems and lab space
- Company website
- Ajay Divakaran, ajay.divakaran@sri.com
 - 781 541 0779

Core Capabilities

Key areas of work

- Clinical studies
 - Sleep and Brain
 - wearable sensors
 - EEG
- AI-ML Algorithms and Applications
 - Multi-modal Modeling
 - Explainable AI and model grounding through human experts
- Software - Suites delivered to Govt and Commercial Clients

Strengths / Capability Highlights

- Causal Analytics
 - Novel Capture of Temporal Dynamics
 - Patents Paper at <https://arxiv.org/abs/2508.1592>
 - Deployed in the field
- Sleep and mental health
 - <https://academic.oup.com/acn/article-abstract/39/7/988/7756000>
- Speech Biomarkers for PTSD
 - <https://pubmed.ncbi.nlm.nih.gov/31006959/>
- Highly qualified AI-ML personnel
- Long track record of taking ideas from concept to realization in the field

Teaming Goals

What are we looking for?

- Clinical Partner with rich data collection ability
Success stories/past performance/key projects & outcomes
- Long record of successfully collaborating with academia, commercial industry and government
- Ability /desire to support follow-on dev't effort
- Desire/willingness to exclusively team?